CN1269528C - 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 - Google Patents
降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 Download PDFInfo
- Publication number
- CN1269528C CN1269528C CNB2003101131191A CN200310113119A CN1269528C CN 1269528 C CN1269528 C CN 1269528C CN B2003101131191 A CNB2003101131191 A CN B2003101131191A CN 200310113119 A CN200310113119 A CN 200310113119A CN 1269528 C CN1269528 C CN 1269528C
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- glp
- peptide
- blood sugar
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 23
- 239000008280 blood Substances 0.000 title claims abstract description 23
- 241000124008 Mammalia Species 0.000 title claims abstract description 10
- 108010016626 Dipeptides Proteins 0.000 title claims description 5
- 239000012636 effector Substances 0.000 title abstract description 15
- 102000035195 Peptidases Human genes 0.000 title description 8
- 108091005804 Peptidases Proteins 0.000 title description 8
- 235000019833 protease Nutrition 0.000 title description 3
- 230000000694 effects Effects 0.000 claims abstract description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 19
- 239000008103 glucose Substances 0.000 claims abstract description 19
- 210000002966 serum Anatomy 0.000 claims abstract description 8
- 230000004060 metabolic process Effects 0.000 claims abstract description 6
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 5
- 239000003112 inhibitor Substances 0.000 claims description 24
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 15
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims description 13
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 9
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 3
- 208000010444 Acidosis Diseases 0.000 claims description 2
- 102000004860 Dipeptidases Human genes 0.000 claims description 2
- 108090001081 Dipeptidases Proteins 0.000 claims description 2
- 206010018473 Glycosuria Diseases 0.000 claims description 2
- 206010027417 Metabolic acidosis Diseases 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 230000035780 glucosuria Effects 0.000 claims description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 1
- 201000005577 familial hyperlipidemia Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 21
- 102000004190 Enzymes Human genes 0.000 abstract description 16
- 108090000790 Enzymes Proteins 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 16
- 229940125396 insulin Drugs 0.000 abstract description 11
- 102000004877 Insulin Human genes 0.000 abstract description 10
- 108090001061 Insulin Proteins 0.000 abstract description 10
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 abstract description 9
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 abstract description 7
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 abstract description 7
- 239000000813 peptide hormone Substances 0.000 abstract description 5
- 108010088406 Glucagon-Like Peptides Proteins 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 4
- 210000000496 pancreas Anatomy 0.000 abstract description 4
- 230000002473 insulinotropic effect Effects 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 210000001821 langerhans cell Anatomy 0.000 abstract description 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 235000014633 carbohydrates Nutrition 0.000 abstract 1
- 230000001364 causal effect Effects 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 229960001031 glucose Drugs 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 13
- ARNUPLMOASAEAN-ASLNEKEESA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-2-yl)pentan-1-one Chemical class CC[C@H](C)[C@H](N)C(=O)C1NCCS1 ARNUPLMOASAEAN-ASLNEKEESA-N 0.000 description 12
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 12
- 239000000758 substrate Substances 0.000 description 11
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 description 9
- 239000000859 incretin Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 4
- 101710178372 Prolyl endopeptidase Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 210000001198 duodenum Anatomy 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 229940125532 enzyme inhibitor Drugs 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000012266 salt solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000005927 Cysteine Proteases Human genes 0.000 description 3
- 108010005843 Cysteine Proteases Proteins 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 241000053227 Themus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- OUCUOMVLTQBZCY-BYPYZUCNSA-N (2s)-1-azaniumylpyrrolidine-2-carboxylate Chemical compound NN1CCC[C@H]1C(O)=O OUCUOMVLTQBZCY-BYPYZUCNSA-N 0.000 description 1
- IVBVTDXOGUNDHC-LURJTMIESA-N (2s)-2-amino-1-pyrrolidin-1-ylpropan-1-one Chemical compound C[C@H](N)C(=O)N1CCCC1 IVBVTDXOGUNDHC-LURJTMIESA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 244000302413 Carum copticum Species 0.000 description 1
- 108010092674 Enkephalins Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 229940126544 HIV-1 protease inhibitor Drugs 0.000 description 1
- FRJIAZKQGSCKPQ-FSPLSTOPSA-N His-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1 FRJIAZKQGSCKPQ-FSPLSTOPSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 101100166829 Mus musculus Cenpk gene Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- FWALKNQZXMYXRH-UHFFFAOYSA-N OC1=C(C(=CC=C1)O)C(C1=C(C=CC=C1)C(C)=O)=O Chemical compound OC1=C(C(=CC=C1)O)C(C1=C(C=CC=C1)C(C)=O)=O FWALKNQZXMYXRH-UHFFFAOYSA-N 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108010084214 Peptide PHI Proteins 0.000 description 1
- 239000000132 Peptide PHI Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- NLKUJNGEGZDXGO-XVKPBYJWSA-N Tyr-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NLKUJNGEGZDXGO-XVKPBYJWSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010038900 X-Pro aminopeptidase Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- XXXHSQBVHSJQKS-UHFFFAOYSA-N amino benzoate Chemical compound NOC(=O)C1=CC=CC=C1 XXXHSQBVHSJQKS-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- YLBIOQUUAYXLJJ-WZUUGAJWSA-N peptide histidine methionine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 YLBIOQUUAYXLJJ-WZUUGAJWSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000004454 trace mineral analysis Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Abstract
本发明涉及一种方法的用途,其中,通过施用效应物来降低哺乳动物血液中二肽基肽酶(DP IV)-以及DP IV类似物-酶活性,将导致内源(或者外源施用)的促胰岛素肽(肠促胰岛素)、抑胃多肽1-42(GIP1-42)以及高血糖素样肽酰胺-17-36(GLP-17-36)(或类似地GLP-17-37或这些肽的类似物)降解至一个较低的含量。由此这些肽激素或其类似物的浓度降低(导致由DP IV和DP IV类似物-酶降解)将被减少或者延迟。由于DP IV效应物的作用,由内源性或外源性施用可得的肠促胰岛素或其类似物的提高了的稳定性改变了内源胰岛素的能力并由此刺激在被处理有机体中碳水物质的代谢。因此被处理有机体血清中血糖水平降低至低于表征高血糖的葡萄糖浓度之下。
Description
本发明是申请日为1997年4月24日、申请号为97194017.7、发明名称为降低哺乳动物血糖水平的二肽基肽酶IV效应物的用途的中国专利申请的分案申请。
技术领域
本发明涉及一种降低血糖浓度的简单的方法,该方法借助对与二肽基肽酶IV的酶促活性有类似或相同的活性的酶进行抑制的效应物(底物、假底物、抑制剂、结合蛋白、抗体和其类似物)来降低血糖浓度。
背景技术
除了与非特异蛋白酶解的蛋白酶有关以外,导致蛋白质特异性降解的蛋白酶为大家所熟知,这与内源性肽的功能调节(活化、失活或调节)有关[KIRSCHKE,H.,LANGNER,J.RIEMANN,S.,WIEDERANDERS,B.,ANSORGE,S.和BOHLEY,P.,溶酶体半胱氨酸蛋白酶.ExcerptaMedica(Ciba基础专题研讨75),15(1980);KRUSSLICH,H.-G.和WIMMER,E.,病毒蛋白酶.生物化学年度综述57,701(1987)]。
在免疫系统研究和神经肽研究中已经发现了所谓的转化酶、信号肽酶或脑腓肽酶[GOMEZ,S.,GLUSCHANKOF,P.,LEPAGE,A.,MARRAKCHI,N.和COHEN,P.美国国家科学院院报85,5468(1988);ANSORGE,S.和SCHN,E.,组织化学82,41(1987)]。
由于氨基酸脯氨酸在许多肽激素中非常丰富且由此决定这些肽的一定结构性质,因此将脯氨酸特异的肽酶当作一种对信号肽酶的有类似功能的酶讨论[YARON,A.,在生物活性肽的蛋白水解调节中脯氨酸的作用。生物高聚物(1987)26,215;WALTER,R.,SIMMONS,W.H.和YOSHIMOTO,T.,脯氨酸特异性内肽酶和外肽酶,分子细胞生物化学30,111(1980);VANHOOF,G.,GOOSSENS,F.,DE MEESTER,I.,HENDRIKS,D.和
,S.,脯氨酸基元和它们的生物加工。FASEB期刊9,736(1995)]。由于它的例外结构,在这种肽中脯氨酸决定着它们的构象和稳定性,以阻止由非特异蛋白酶导致的降解。[KESSLER,H.,构象和生物活性。应用化学94,509(1982)]。相对地,对脯氨酸包含的序列(包括HIV-蛋白酶,cyclophylin等等)具有高度特异性能力的酶是药物化学的具有吸引力的靶。尤其是,将后脯氨酸切割的肽酶(如脯氨酰内肽酶(PEP)和二肽基肽酶IV(DP IV)的活性)与天然肽底物的生物活性的调节和它们的由这些酶的选择性切割联系起来。有人指出PEP与记忆和学习有关,并且DP IV在免疫应答期间参与信号转导[ISHIURA,S.,TSUKAHARA,T.TABIRA,T.SHIMLZU,T.,ARAHATA K和SUGITA,H.,FEBS-通讯(1990)260,131;HEGEN,M.,NIEDOBITEK,G.,KLEIN,C.E.,STEIN,H.和FLETSCHER,B.,免疫学杂志144,2908(1990)]。
除它们有突出的相似于高脯氨酸的特异性之外,在这些酶的底物的典型识别区中有能够选择性地识别氨基酸丙氨酸的高选择性。据此,人们认为含丙氨酸的肽在结构上可采用与结构类似的含脯氨酸的肽类似的构象。前不久,含脯氨酸的肽链的这类性质已通过基因点突变(脯氨酸交换丙氨酸)[DODGE R.W.和SCHERAGA,H.A.,牛胰核糖核酸酶A的脯氨酸-向-丙氨酸突变体的折叠和解折叠动力学,生物化学35(5)1548(1996)]。
在由生物活性肽的N端释放高活性二肽的地方,当脯氨酸或丙氨酸是序列中N-末端氨基酸的相邻残基时,血液循环中存在的DPIV-或DP IV类似物-的活性(例如胞质DP II具有与DP IV的几乎同样的底物特异性)是高度特异性的。因此,这种酶参与了体内多肽的活性调节[VANHOOF,G.,COOSSENS,F.,DE MEESTER,I.,HENDRIKS,D.和
,S.,脯氨酸基元和它们的生物加工,FASEB期刊9,736(1995)]。
糖依赖性胰岛素释放肽:抑胃多肽1-42(GIP1-42)和胰高血糖素样肽酰胺-1 7-36(GLP-17-36)-它们是刺激从胰腺(肠促胰岛素)分泌葡萄糖诱导的胰岛素的激素-是DP IV的底物,因为它们分别在体外和体内从这些肽的N-末端序列释放二肽酪氨酰-丙氨酸和组氨酰-丙氨酸[MENTLEIN,R.,GALLWITZ,B.,和SCHMLDT,W.E.:二肽基肽酶IV水解抑胃多肽、胰高血糖素样肽-1(7-36)酰胺、肽组氨酸甲硫氨酸,并且在人血清中对它们的降解负责,欧洲生物化学杂志214,829(1993)]。
在哺乳动物中,在实验室条件和病理状态下,在体内降低由DPIV-或DP IV类似物-酶活性对这种底物的切割可能用于有效抑制不合乎需要的酶促活性[DEMUTH,H.-U.,在丝氨酸和半胱氨酸蛋白酶的不可逆抑制方面的最新进展,酶抑制杂志,3,249-278(1990);DEMUTH,H.-U.和HEINS,J.,在二肽基肽酶IV(CD 26)的代谢和免疫应答中二肽基肽酶IV的催化机理(B.Fleischer,编著)R.G.Landes,生物药物出版社,Georgetown,1-35(1995)]。例如,II型真性糖尿病(以及老年性糖尿病)是基于胰岛素分泌受阻或受体功能的紊乱,除了其它因素外,这是酶解决定的分泌物浓度异常的原因[BROWN,J.C.,DAHL,M.,KWAWK,S.,MCINTOSH,C.H.S.,OTTE,S.C和PEDERSON,R.A.肽2,241(1981);SCHMLDT,W.E.SIEGEL,E.G.,GALLWITZ,B.KUMMEL,H.,EBERT,R和CREUTZFELDT,W.,从抑胃多肽衍生的片段的促胰岛素活性的鉴定,糖尿病生理学29,591A(1986);ADELHORST,K.,HEDEGAARD,B.B.,KNUDSEN,L.B.和KIRK,O.,胰高血糖素样肽的结构活性研究,生物化学杂志296,6275(1994)]。
按照现有技术,通过利用不同的施用形式给患者施用胰岛素(例如从牛或猪胰分离的或者由基因工程获得的材料)来治疗高血糖和与此有关的病因和后遗症。至今已知的以及较现代的治疗方法表现出高耗费以及对患者身体状况的强烈损害。经典的方法(每日进行静脉内胰岛素注射,从三十年代就已经利用)处理急性症状,但是在应用较长时间后将导致血管变形(动脉硬化)和神经性损伤[LACY,P.,脉间区细胞移植的状态,糖尿病护理16(3)76(1993)]。
更现代的方法,如皮下贮存植入物的安装(成功地计量胰岛素释放,取消每日注射)以及在功能紊乱的胰腺或其它器官和组织中植入朗氏细胞完整脉间区(移植)正在试验中。然而,这样的移植昂贵。另外,它们表示出高风险的外科手术排斥反应,并且在采用移植方法时要求进行免疫抑制或者避开免疫应答。[LACY,P.,用移植细胞治疗糖尿病,美国科学273(1)40-46(1995)]。
与上述疗法相比,尽可能地口服高效的低分子量酶抑制剂是在处理病理现象时的、一种对于例如侵害性的外科手术方法的非常有效的替代选择方案。这类酶抑制剂找到了在治疗中的用途,以用作抗高血压药物、免疫抑制药物以及抗艾滋病毒剂。通过对分子的稳定性、转录和裂变性质进行化学设计,可以改进它们的功效,并且使它们在有机体之间适应个体的区别。[SANDLER,M.和SMLTH,H.J.,编著,作为药物的酶抑制剂的设计,牛津大学出版社,牛津大学(1989);MUNROE,J.E.,SHEPHEAD,T.A.,JUNGHEIM,L.N.,HORNBACK,W.J.,HATCH,S.D.,MUESTNG,M.A.,WISKERCHEN,M.A.,SU,K.S.,CAMPANALE,K.M.,BAXTER,A.J.和COLACINO,J.M.,包含非编码的D-氨基酸的有效的口服的HIV-1蛋白酶抑制剂,生物药物化学通讯5(23)2987(1995)]。
发明内容
本发明的目的是提供一种降低血糖水平的简单的并且新的方法,其中通过给哺乳动物服用酶的效应物,使所说酶的效应物诱导DP IV-酶的或者DP IV类似物-酶的活性降低,这将导致内源的(或外源施用的)促胰岛素肽抑胃多肽1-42(GIP1-42)和胰高血糖素样肽酰胺-17-36(GLP-17-36或这些肽的类似物)的降解减少。因此,将阻止或者延迟这些肽激素或它们类似物在浓度上的减少。
本发明基于这样一个惊人的发现:在血液循环中,二肽基肽酶DP IV酶的或者DP IV类似物-酶的活性降低将导致改进的葡萄糖耐受性。我们观察到:
1.降低二肽基肽酶DP IV-或DP IV类似物-酶活性导致葡萄糖刺激的内源释放的或外源施用的肠降血糖素(或其类似物)稳定性相对地提高,因此通过服用DP IV-或DP IV类似物-蛋白质的活性抑制效应物,可以控制肠降血糖素在血液中的降解。
2.肠降血糖素(或其类似物)的提高了的生物降解稳定性导致胰岛素作用效果改进。
3.由降低二肽基肽酶DP IV-或DP IV类似物-酶活性引起的肠降血糖素稳定性的升高将导致葡萄糖诱导的胰岛素作用随后改变,且借此导致一种可借助DP IV效应物控制性调节的血糖水平。
因此,本发明涉及二肽基肽酶DP IV-或者DP IV类似物-酶活性的活性抑制效应物的用途,用于将血糖水平降低至哺乳动物血中表征高血糖水平的葡萄糖浓度之下。本发明尤其涉及DP IV-或DP IV类似物-酶活性效应物在预防或者减轻哺乳动物代谢中的病理变态如葡糖尿、超脂血症、代谢性酸中毒和糖尿病中的应用。在一个更优选的实施方案中,本发明涉及降低哺乳动物血中血糖浓度至表征高血糖水平的葡萄糖浓度之下的方法。其特征在于,给哺乳动物服用治疗有效量的二肽基肽酶DP IV-或DP IV类似物-酶活性的效应物。
在第二个优选的实施方案中,本发明涉及二肽基肽酶DP IV-或DP IV类似物-酶活性的活性抑制效应物,它用于降低哺乳动物血中血糖浓度至表征提高血糖葡萄糖浓度之下的方法中。
按照本发明,施用的DP IV-和DP IV类似物-酶的活性抑制效应物作为酶抑制剂、底物、假底物、DP IV-表达物的抑制剂、结合蛋白或所说的酶蛋白的抗体或者作为这些不同化合物的组合体用于可用作药物的配方复合体中,这些效应物减少在哺乳动物中DP IV-和DP IV类似物-蛋白质的浓度。按照本发明的效应物例如是DPIV-抑制物如二肽衍生物或如丙氨酰-吡咯烷酰胺(pyrolidid)、异亮氨酰-四氢噻唑之类的二肽模仿物,以及假底物N-结氨酰-脯氨酰,O-苯甲酰羟胺。这些化合物从文献中是已知的[DEMUTH,H.-U.,在丝氨酸以及半胱氨酸蛋白酶的不可逆抑制方面的最新进展,酶抑制杂志3,249(1990)],或者可以按照文献所描述的方法进行合成。
按照本发明的方法是一种降低哺乳动物血液中升高了的血糖浓度的新方法。本方法简单、制药学上有用,并且适用于制备治疗尤其是人类疾病的药物,这些疾病是基于超过正常血糖水平引起的。
将效应物以药物制剂形式进行施用,该制剂包含有效成分和常规的、从现有技术已知的载体材料。例如将它们以肠胃外(静脉内,以生理盐溶液)或经肠道(口服,与通常的载体材料形成配方)施用。
取决于效应物的内源稳定性和生物利用率,要进行一次或多次给药,以达到所预期的血糖浓度正常化。例如在用氨基酰基-四氢噻唑的情况下,剂量可以在1.0-10.0mg效应物物质/kg的范围内变化。
附图说明
附图1显示了对GIP1-42(b)和GLP-7-36用DP IV催化的水解和异亮氨酰-四氢噻唑对它们的抑制进行MALDI-TOF-分析
附图2显示了体内存在或不存在DP IV抑制剂异亮氨酰-四氢噻唑时GLP-1代谢物在血清中含量的HPLC-分析
附图3显示了DP IV-抑制剂异亮氨酰-四氢噻唑对十二指肠内葡萄糖刺激的鼠的不同血参数的影响
具体实施方式
实施例1.在体内肠促胰岛素GIP-1-42和GLP-17-36的DP IV-催化水解的抑制作用
体内利用纯化的酶或现场利用混合人血清可以证明,由DP IV-和DP IV类似物-酶促活性引起的肠促胰岛素的水解、或借助抑制剂可对它进行抑制(图1)。
按照本发明,在体内通过温育30μM GIP1-42或30μM GLP-17-36和20μM异亮氨酰-四氢噻唑(1a),在24小时内实现对两种肽激素的酶催化水解的完全抑制(1b和1c,各见上面谱图),上述温育物在pH7.6和30℃下是在20%混合血清中的可逆DP IV-抑制物。在pH7.6和30℃下,将合成的抑胃多肽GIP1-42(5μM)和合成的GLP-17-36(15μM)用在0.1mM TRICINE缓冲液中的人血清(20%)温育24小时。在不同时间间隔之后,取出温育分析样品(对于GIP1-422.5pmol,对于GLP-17-36 7.5pmol)。将样品利用2′,6′-二羟乙酰苯酮作为基质进行共结晶,并且通过MALDI-TOF-质谱分析法进行分析。谱图(图1)显示,每样品中有250个单个激光激发的积累。
(1b)在范围m/z 4980.1±5.3中的信号对应于GIP1-42(M4975.6),并且在范围m/z 4745.2±5.5中的信号对应于DP IV-水解产物GLP-13-42(M4740.4)。
(1c)信号m/z 3325.0±1.2对应于GLP-17-36(M3297.7),并且信号m/z 3116.7±1.3对应于DP IV-水解产物GLP-19-36(M3089.6)。
在不包含任何抑制剂的参照分析试样中,在这种时间内肠促胰岛素几乎完全降解(图1b和1c,各见下面的谱图)。
实施例2.通过体内的DP IV-抑制剂异亮氨酰-四氢噻唑抑制GLP-17-36的降解
与一个对照样相对照,跟踪分析鼠血清中天然肠促胰岛素(此处为GLP-17-36)的代谢对DP IV-抑制剂异亮氨酰-四氢噻唑(静脉内注射包含1.5μM抑制剂的0.9%食盐溶液)的依赖关系。在用抑制剂处理过的供试动物(N=5)中,以浓度为每千克供试鼠用0.1mg抑制剂异亮氨酰-四氢噻唑试验时,促胰岛素肽激素GLP-17-36在实验期间没有观察到发生了降解(图2)。
在存在和不存在DP IV-抑制剂时,为了检测肠促胰岛素的代谢物,在开始静脉内施用抑制剂或食盐水20分钟后,将供验和参照动物进一步静脉内注射50-100pM 125I-GLP-17-36(大约1μCi/pM比活)。温育2-5分钟后收集血样,并且利用20%乙腈提取原生质。随后,在RP-HPLC上分离所说的肽提取物并且在γ-计数器上分析样品的放射活性。将实测数据表达为相对于最大值的每分钟计数次数(cpm)。
实施例3.在体内静脉内施用DP IV-抑制剂异亮氨酰-四氢噻唑后胰岛素作用的调节和血糖水平的下降。
在通过对十二指肠内(i.d.)注射葡萄糖刺激的鼠身上,可通过体内施用不同的DP IV-效应物例如每千克鼠重0.1mg异亮氨酰-四氢噻唑,观测到归因于抑制剂效果的、时间上延迟发生作用的葡萄糖水平下降。这种效果取决于剂量,且在停止注射每千克鼠重0.05mg/分钟DP IV-抑制剂异亮氨酰-四氢噻唑后,效果是可逆的。与十二指肠内葡萄糖刺激的供试动物相反,将抑制剂处理的和对照用的动物作静脉内施用相同量的葡萄糖后,没有观察到可比的作用。图3显示了这些抑制剂依赖性的原生质参数的改变:A-DP IV-活性、B-原生质-胰岛素水平、C-血糖水平。
试验动物(N=5,雄性Wistar-鼠,200-225g)最初获得含于0.9%食盐溶液中的1.5μM异亮氨酰-四氢噻唑(▲)或不含抑制剂的相同体积0.9%食盐溶液(■)(对照组,n=5)。试验组在30分钟实验时间内另外获得0.75μM/分钟的抑制剂注射(*)。将对照组在相同的时间间隔期间注入0.9%的无抑制剂的食盐溶液。在开始时间T=0时,将所有动物十二指肠内施用葡萄糖剂量为1g/kg 40%的葡萄糖溶液(w/v)。
在10分钟时间间隔内收集所有试验动物的血样。当在原生质中的DP IV-活性和胰岛素浓度被分析时,利用全血(Lifescan OneTouch II分析器)分析葡萄糖含量。
所采用的胰岛素测定法在10至160mU/ml的范围内是敏感的[PEDERSON,R.A.,BUCHAN,A.M.J.,ZAHEDI-ASH,S.,CHEN,C.B.和BROWN,J.C.Reg.Peptides.3,(1982)]。通过光谱分析法确定DP IV-活性[DEMUTH,H.-U.和HEINSI J.,二肽基肽酶IV(CD26)在代谢和免疫应答中二肽基肽酶IV的催化机理,(B.Fleischer,编)R.G.Landes,生物医学出版社,Georgetown,1-35(1995)]。所有数据以平均值加标准偏差给出。
Claims (5)
1.二肽基肽酶IV的酶活性抑制剂用于制备药物的用途,所述药物用于口服给药通过降低哺乳动物血清中的血糖水平来治疗基于表征高血糖的哺乳动物血清中的葡萄糖浓度的疾病。
2.按照权利要求1的用途,其特征在于,所述药物用于预防或者减轻下列哺乳动物代谢病理异常:葡糖尿,高脂血症,代谢性酸中毒或糖尿病。
3.按照权利要求1的用途,其特征在于,其中所述抑制剂能够降低二肽基肽酶IV针对GIP1-42和GLP-17-36的活性。
4.按照权利要求1的用途,其特征在于所述抑制剂是二肽衍生物或二肽模拟物。
5.按照权利要求1的用途,其特征在于,所述抑制剂是氨酰-四氢噻唑。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19616486.9 | 1996-04-25 | ||
DE19616486.9A DE19616486C5 (de) | 1996-04-25 | 1996-04-25 | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97194017A Division CN1132578C (zh) | 1996-04-25 | 1997-04-24 | 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1535681A CN1535681A (zh) | 2004-10-13 |
CN1269528C true CN1269528C (zh) | 2006-08-16 |
Family
ID=7792391
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101131191A Expired - Lifetime CN1269528C (zh) | 1996-04-25 | 1997-04-24 | 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 |
CN97194017A Expired - Lifetime CN1132578C (zh) | 1996-04-25 | 1997-04-24 | 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN97194017A Expired - Lifetime CN1132578C (zh) | 1996-04-25 | 1997-04-24 | 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 |
Country Status (22)
Country | Link |
---|---|
US (1) | US6303661B1 (zh) |
EP (3) | EP2289513A3 (zh) |
JP (3) | JP2001510442A (zh) |
KR (5) | KR100950722B1 (zh) |
CN (2) | CN1269528C (zh) |
AT (1) | ATE202705T1 (zh) |
AU (1) | AU721477C (zh) |
CA (1) | CA2252576C (zh) |
DE (5) | DE122010000020I1 (zh) |
DK (2) | DK1084705T3 (zh) |
ES (2) | ES2505665T3 (zh) |
FR (1) | FR14C0089I1 (zh) |
GR (1) | GR3036788T3 (zh) |
HK (2) | HK1019204A1 (zh) |
LT (3) | LTPA2014044I1 (zh) |
LU (7) | LU91334I2 (zh) |
NL (2) | NL300280I2 (zh) |
NZ (1) | NZ332707A (zh) |
PT (2) | PT1084705E (zh) |
RU (1) | RU2189233C2 (zh) |
SI (1) | SI1084705T1 (zh) |
WO (1) | WO1997040832A1 (zh) |
Families Citing this family (291)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US20020006899A1 (en) * | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
US6258597B1 (en) * | 1997-09-29 | 2001-07-10 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
WO1999025719A1 (fr) * | 1997-11-18 | 1999-05-27 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Substance physiologiquement active, la sulphostine, procede de fabrication et utilisation |
WO1999038501A2 (en) | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
AU2007202745B2 (en) * | 1998-02-02 | 2010-11-18 | 1149336 Ontario, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
US6255772B1 (en) | 1998-02-27 | 2001-07-03 | Micron Technology, Inc. | Large-area FED apparatus and method for making same |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
DE19828114A1 (de) * | 1998-06-24 | 2000-01-27 | Probiodrug Ges Fuer Arzneim | Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV |
DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
DE19834591A1 (de) * | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Verfahren zur Steigerung des Blutglukosespiegels in Säugern |
US6979697B1 (en) | 1998-08-21 | 2005-12-27 | Point Therapeutics, Inc. | Regulation of substrate activity |
US20030176357A1 (en) * | 1998-10-06 | 2003-09-18 | Pospisilik Andrew J. | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels |
DK1171465T3 (da) | 1999-03-29 | 2004-12-13 | Uutech Ltd | Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes |
US20050272652A1 (en) | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
US6890904B1 (en) * | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
DE19926233C1 (de) | 1999-06-10 | 2000-10-19 | Probiodrug Ges Fuer Arzneim | Verfahren zur Herstellung von Thiazolidin |
DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
JP2003535034A (ja) * | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼiv阻害剤並びにジペプチジルペプチダーゼiv阻害剤の製造及び使用法 |
GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
JP2003518496A (ja) * | 1999-12-23 | 2003-06-10 | ノバルティス アクチエンゲゼルシャフト | グルコース代謝障害を処置するための血糖降下薬の使用 |
US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
PT1741447E (pt) | 2000-01-21 | 2013-12-11 | Novartis Ag | Combinações que compreendem o inibidor da dipeptidilpeptidase-iv |
AU2001228309A1 (en) * | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
JP2003523396A (ja) * | 2000-02-25 | 2003-08-05 | ノボ ノルディスク アクティーゼルスカブ | ベータ細胞変性の抑制 |
US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
US6500804B2 (en) * | 2000-03-31 | 2002-12-31 | Probiodrug Ag | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
AR033390A1 (es) | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
EP1891948A1 (en) | 2000-10-27 | 2008-02-27 | Probiodrug AG | Treatment of neurological and neuropsychological disorders |
US7132104B1 (en) | 2000-10-27 | 2006-11-07 | Probiodrug Ag | Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders |
IL155116A0 (en) * | 2000-10-27 | 2003-10-31 | Probiodrug Ag | Pharmaceutical compositions containing as inhibitor of dipeptidyl peptidase iv and of similar enzymes |
DE60139087D1 (de) * | 2000-12-14 | 2009-08-06 | Ortho Mcneil Janssen Pharm | Verfahren zu Herstellung von Zubereitungen enthaltend einen Steroidhormon und ein Stabilisierungsmittel in nicht-kristallinen Form |
JPWO2002051836A1 (ja) * | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−iv阻害剤 |
DE10100053A1 (de) * | 2001-01-02 | 2002-08-22 | Keyneurotek Ag I G | Verwendung von Enzyminhibitoren der Dipeptidylpeptidase IV sowie der Aminopeptidase N und pharmazeutischen Zubereitungen daraus zur Prävention und/oder Therapie Ischämie-bedingter akuter und chronischer neurodegenerativer Prozesse und Erkrankungen |
KR100883277B1 (ko) * | 2001-02-24 | 2009-02-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체 및 이의 제조방법 |
US7026316B2 (en) | 2001-03-27 | 2006-04-11 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US6890905B2 (en) | 2001-04-02 | 2005-05-10 | Prosidion Limited | Methods for improving islet signaling in diabetes mellitus and for its prevention |
GB0109146D0 (en) * | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
US20030060494A1 (en) * | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
FR2826003B1 (fr) * | 2001-06-18 | 2003-08-15 | Servier Lab | Nouveaux derives cycliques d'alpha-amino-gamma-hydroxy- amides, leur procede de preparation et les compositions pharmaceutiques que les contiennent |
EP1406872B1 (en) | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
US7253172B2 (en) | 2001-06-20 | 2007-08-07 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
DE10150203A1 (de) | 2001-10-12 | 2003-04-17 | Probiodrug Ag | Peptidylketone als Inhibitoren der DPIV |
ATE374181T1 (de) | 2001-06-27 | 2007-10-15 | Smithkline Beecham Corp | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
US7368421B2 (en) | 2001-06-27 | 2008-05-06 | Probiodrug Ag | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis |
US20030130199A1 (en) | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
EP1492525A2 (en) * | 2001-08-16 | 2005-01-05 | Probiodrug AG | Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
US6844316B2 (en) | 2001-09-06 | 2005-01-18 | Probiodrug Ag | Inhibitors of dipeptidyl peptidase I |
US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
AU2002360453C1 (en) | 2001-11-26 | 2009-06-18 | The Brigham And Women's Hospital, Inc. | Methods for treating autoimmune disorders, and reagents related thereto |
KR20040058324A (ko) * | 2001-11-26 | 2004-07-03 | 다이이찌 산토리 파마 가부시키가이샤 | 경비흡수용 의약 조성물 |
EP2316470A3 (en) | 2001-11-26 | 2011-08-24 | Trustees Of Tufts College | Peptidomimetic inhibitors of post-proline cleaving enzymes |
AU2003206833B2 (en) | 2002-02-13 | 2006-07-20 | F. Hoffmann-La Roche Ag | Novel pyridin- and pyrimidin-derivatives |
WO2003068748A1 (en) | 2002-02-13 | 2003-08-21 | F. Hoffmann-La Roche Ag | Novel pyridine- and quinoline-derivatives |
DE60304911D1 (de) * | 2002-02-25 | 2006-06-08 | Eisai Co Ltd | Xanthin-Derivate als DPP-IV-Inhibitoren |
PL372316A1 (en) | 2002-02-28 | 2005-07-11 | Prosidion Limited | Glutaminyl based dpiv inhibitors |
GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
DE10211555A1 (de) * | 2002-03-15 | 2003-10-02 | Imtm Inst Fuer Medizintechnolo | Verwendung der Inhibitoren von Enzymen mit Aktivitäten der Aminopeptidase N und/oder der Dipeptidylpeptidase IV und pharmazeutischen Zubereitungen daraus zur Therapie und Prävention dermatologischer Erkrankungen mit sebozytärer Hyperproliferation und veränderten Differenzierungszuständen |
EP1490335B1 (en) * | 2002-03-25 | 2007-09-19 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US20030232761A1 (en) * | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
RU2362555C2 (ru) * | 2002-06-03 | 2009-07-27 | Новартис Аг | Применение замещенных цианопирролидинов и содержащих их комбинированных препаратов для лечения гиперлипидемии и ассоциированных заболеваний |
US6710040B1 (en) | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
ATE451369T1 (de) * | 2002-07-15 | 2009-12-15 | Merck & Co Inc | Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7569574B2 (en) | 2002-08-22 | 2009-08-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Purine derivatives, the preparation thereof and their use as pharmaceutical compositions |
US7495005B2 (en) * | 2002-08-22 | 2009-02-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, their preparation and their use in pharmaceutical compositions |
DE60331747D1 (de) * | 2002-09-18 | 2010-04-29 | Prosidion Ltd | Sekundäre bindungsstelle von dipeptidylpeptidase iv (dp iv) |
US20040058876A1 (en) * | 2002-09-18 | 2004-03-25 | Torsten Hoffmann | Secondary binding site of dipeptidyl peptidase IV (DP IV) |
US7262207B2 (en) | 2002-09-19 | 2007-08-28 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
JP4491346B2 (ja) * | 2002-10-07 | 2010-06-30 | メルク・シャープ・エンド・ドーム・コーポレイション | 抗糖尿病ベータアミノ複素環ジペプチジルペプチダーゼ阻害剤 |
AU2003298596B2 (en) * | 2002-10-18 | 2008-12-18 | Merck Sharp & Dohme Corp. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
KR20050072481A (ko) | 2002-11-07 | 2005-07-11 | 머크 앤드 캄파니 인코포레이티드 | 당뇨병의 치료 또는 예방을 위한 디펩티딜 펩티다제억제제로서의 페닐알라닌 유도체 |
US7482337B2 (en) * | 2002-11-08 | 2009-01-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions |
DE10254304A1 (de) * | 2002-11-21 | 2004-06-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel |
JP2006510630A (ja) * | 2002-12-04 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体 |
AU2003297219A1 (en) * | 2002-12-20 | 2004-07-22 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004065380A1 (en) | 2003-01-14 | 2004-08-05 | Arena Pharmaceuticals Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
AU2004206812A1 (en) | 2003-01-17 | 2004-08-05 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
JP2006516573A (ja) | 2003-01-31 | 2006-07-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体 |
WO2004067509A1 (ja) * | 2003-01-31 | 2004-08-12 | Sanwa Kagaku Kenkyusho Co., Ltd. | ジペプチジルペプチダーゼivを阻害する化合物 |
US20040242566A1 (en) | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
KR20110059664A (ko) | 2003-05-05 | 2011-06-02 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제의 이펙터의 용도 |
MXPA05011861A (es) | 2003-05-05 | 2006-02-17 | Probiodrug Ag | Uso de efectores de ciclasas de glutamato y glutaminil. |
EP1625122A1 (en) | 2003-05-14 | 2006-02-15 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
JP2006528693A (ja) | 2003-05-14 | 2006-12-21 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としての3−アミノ−4−フェニルブタン酸誘導体 |
ATE463492T1 (de) | 2003-06-06 | 2010-04-15 | Merck Sharp & Dohme | Kondensierte indole als dipeptidyl-peptidase- hemmer zur behandlung oder prävention von diabetes |
US7456204B2 (en) | 2003-06-17 | 2008-11-25 | Merck & Co., Inc. | Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
US7566707B2 (en) * | 2003-06-18 | 2009-07-28 | Boehringer Ingelheim International Gmbh | Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions |
ATE437876T1 (de) | 2003-06-20 | 2009-08-15 | Hoffmann La Roche | Hexahydropyridoisochinoline als dpp-iv- inhibitoren |
DE602004030244D1 (de) | 2003-06-20 | 2011-01-05 | Hoffmann La Roche | Itoren |
EP2085406A1 (en) * | 2003-07-25 | 2009-08-05 | ConjuChem Biotechnologies Inc. | Long lasting insulin derivatives and methods thereof |
AU2004261186A1 (en) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US7579357B2 (en) | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
KR101121882B1 (ko) | 2003-10-15 | 2012-04-12 | 프로비오드룩 아게 | 글루타미닐 및 글루타메이트 사이클라제 이펙터의 용도 |
AU2004285535A1 (en) * | 2003-10-31 | 2005-05-12 | Alza Corporation | Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin |
US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US20100099721A1 (en) * | 2003-11-03 | 2010-04-22 | Probiodrug Ag | Novel compounds for the treatment of neurological disorders |
JP2007509898A (ja) | 2003-11-03 | 2007-04-19 | プロビオドルグ エージー | 神経障害治療に有用な組合せ |
AU2004286857A1 (en) * | 2003-11-04 | 2005-05-19 | Merck & Co., Inc. | Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
US7576121B2 (en) | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
ES2524916T3 (es) | 2003-11-12 | 2014-12-15 | Sino-Med International Alliance, Inc. | Compuestos heterocíclicos de ácido borónico |
US7767828B2 (en) | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
KR20180050427A (ko) | 2003-11-17 | 2018-05-14 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
DE10355304A1 (de) * | 2003-11-27 | 2005-06-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
ES2940341T3 (es) | 2004-01-20 | 2023-05-05 | Novartis Ag | Formulación y proceso de compresión directa |
US7230002B2 (en) | 2004-02-03 | 2007-06-12 | Glenmark Pharmaceuticals Ltd. | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof |
EP1713780B1 (en) | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
PL1712547T3 (pl) * | 2004-02-05 | 2012-04-30 | Kyorin Seiyaku Kk | Pochodna bicykloestrowa |
US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004009039A1 (de) * | 2004-02-23 | 2005-09-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel |
EP1593671A1 (en) * | 2004-03-05 | 2005-11-09 | Graffinity Pharmaceuticals AG | DPP-IV inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7393847B2 (en) * | 2004-03-13 | 2008-07-01 | Boehringer Ingleheim International Gmbh | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions |
BRPI0418639B8 (pt) | 2004-03-15 | 2021-05-25 | Takeda Pharmaceutical | compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos |
US7179809B2 (en) * | 2004-04-10 | 2007-02-20 | Boehringer Ingelheim International Gmbh | 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions |
WO2005108382A1 (en) | 2004-05-04 | 2005-11-17 | Merck & Co., Inc. | 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
US7439370B2 (en) | 2004-05-10 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides |
CA2564884A1 (en) | 2004-05-18 | 2005-12-08 | Merck & Co., Inc. | Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
EP1598341A1 (en) * | 2004-05-21 | 2005-11-23 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
EP1604980A1 (en) * | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
EP1604989A1 (en) * | 2004-06-08 | 2005-12-14 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | DPP-IV inhibitors |
DE102004030502A1 (de) | 2004-06-24 | 2006-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
JP2008507541A (ja) * | 2004-07-23 | 2008-03-13 | ロイヤルティ,スーザン・マリー | ペプチダーゼ阻害剤 |
EP1623983A1 (en) * | 2004-08-05 | 2006-02-08 | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft | Heterocyclic compounds useful as DPP-IV inhibitors |
DE102004043944A1 (de) * | 2004-09-11 | 2006-03-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
DE102004044221A1 (de) * | 2004-09-14 | 2006-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
AP2007003973A0 (en) | 2004-10-12 | 2007-07-30 | Glenmark Pharmaceuticals Sa | Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
KR100917545B1 (ko) * | 2004-11-30 | 2009-09-16 | 에프. 호프만-라 로슈 아게 | 당뇨병 치료를 위한 dpp-ⅳ 억제제로서의 치환된벤조퀴놀리진 |
US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
AU2005318597A1 (en) * | 2004-12-20 | 2006-06-29 | F. Hoffmann-La Roche Ag | 4-aminopiperidine derivatives |
EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
MX2007009760A (es) | 2005-02-11 | 2007-11-07 | Amylin Pharmaceuticals Inc | Polipeptidos del analogo e hibrido del peptido inhibidor gastrico con propiedades seleccionables. |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
CN101119991B (zh) | 2005-02-18 | 2012-01-25 | 田边三菱制药株式会社 | 脯氨酸衍生物的盐,其溶剂合物,及其生产方法 |
MX2007011453A (es) | 2005-04-22 | 2008-02-12 | Alantos Pharmaceuticals Holding Inc | Inhibidores de la dipeptidil peptidasa-iv. |
WO2006118127A1 (ja) * | 2005-04-26 | 2006-11-09 | Mitsubishi Tanabe Pharma Corporation | 糖・脂質代謝異常の予防及び/又は治療薬 |
US7521557B2 (en) * | 2005-05-20 | 2009-04-21 | Bristol-Myers Squibb Company | Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods |
US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
AU2006255097B2 (en) | 2005-06-06 | 2012-02-09 | Georgetown University | Compositions and methods for lipo modeling |
DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
CA2622069A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
EP1937716A2 (en) * | 2005-09-08 | 2008-07-02 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
CN101374523B (zh) | 2005-09-14 | 2012-04-11 | 武田药品工业株式会社 | 用于治疗糖尿病的二肽基肽酶抑制剂 |
JP5122462B2 (ja) | 2005-09-16 | 2013-01-16 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
EP1971614A1 (en) * | 2005-11-14 | 2008-09-24 | Probiodrug AG | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors |
DE102005054994B4 (de) * | 2005-11-18 | 2015-02-12 | Bader Gmbh & Co. Kg | Verkleidungsanordnung, insbesondere Maschinenverkleidung, mit einer Schiebetür und Führungsanordnung hierfür |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
US7915427B2 (en) * | 2006-03-08 | 2011-03-29 | Kyorin Pharmaceuticals Co., Ltd. | Process for producing aminoacetyl pyrrolidine carbonitrile derivative and intermediate for production thereof |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
DK1971862T3 (da) | 2006-04-11 | 2011-02-14 | Arena Pharm Inc | Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
EA200802054A1 (ru) | 2006-04-12 | 2009-04-28 | Пробиодруг Аг | Ингибиторы фермента |
CN101437823B (zh) | 2006-05-04 | 2014-12-10 | 勃林格殷格翰国际有限公司 | 多晶型 |
EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20110235A1 (es) * | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
US8071583B2 (en) * | 2006-08-08 | 2011-12-06 | Boehringer Ingelheim International Gmbh | Pyrrolo[3,2-D] pyrimidines as DPP-IV inhibitors for the treatment of diabetes mellitus |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
SI2073810T1 (sl) * | 2006-09-13 | 2011-12-30 | Takeda Pharmaceutical | Uporaba 2-6(3-amino-piperidin-1-il)-3-metil-2,4-diokso-3,4-dihidro-2H-pirimidin -1-ilmetil-4-fluoro-benzonitrila za zdravljenje diabetesa, raka, avtoimunskih motenj in infekcije s HIV |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての3−ヒドロキシ−1,5−ジヒドロ−ピロール−2−オン誘導体 |
US8217025B2 (en) * | 2006-11-17 | 2012-07-10 | Harbor Therapeutics, Inc. | Drug screening and treatment methods |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
US8143427B2 (en) * | 2007-03-22 | 2012-03-27 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
WO2008120813A1 (ja) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | ジペプチジルペプチダーゼ4阻害化合物と甘味料との併用 |
DK2142514T3 (da) | 2007-04-18 | 2015-03-23 | Probiodrug Ag | Thioureaderivater som glutaminylcyclase-inhibitorer |
US7820666B2 (en) | 2007-05-08 | 2010-10-26 | Concert Pharmaceuticals, Inc. | Tetrahydrotriazolopyrazine derivatives and uses thereof |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
PE20090938A1 (es) * | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
CN101784278A (zh) * | 2007-08-17 | 2010-07-21 | 贝林格尔.英格海姆国际有限公司 | 用于治疗fab-相关的疾病的嘌呤衍生物 |
US20090076013A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched sitagliptin |
CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
EP2108960A1 (en) | 2008-04-07 | 2009-10-14 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditons modulated by PYY |
PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
PL2586782T5 (pl) | 2008-07-03 | 2018-05-30 | Ratiopharm Gmbh | Krystaliczne sole sitagliptyny |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
WO2010016584A1 (ja) * | 2008-08-07 | 2010-02-11 | 杏林製薬株式会社 | ビシクロ[2.2.2]オクチルアミン誘導体の製造方法 |
EP2327406A4 (en) * | 2008-08-14 | 2014-04-09 | Kyorin Seiyaku Kk | STABILIZED PHARMACEUTICAL COMPOSITION |
JP5906086B2 (ja) * | 2008-08-15 | 2016-04-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Fab関連疾患の治療に用いるためのプリン誘導体 |
KR20110067096A (ko) | 2008-09-10 | 2011-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
JP2012509892A (ja) | 2008-11-26 | 2012-04-26 | サティオゲン ファーマシューティカルズ,インク. | サティオゲン類を含有する組成物及び使用の方法 |
WO2010062861A2 (en) * | 2008-11-26 | 2010-06-03 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of obesity and diabetes |
KR20110103968A (ko) | 2008-12-23 | 2011-09-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 유기 화합물의 염 형태 |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
US8404727B2 (en) | 2009-01-07 | 2013-03-26 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition that includes a dipeptidyl peptidase-IV inhibitor |
LT2395983T (lt) | 2009-02-13 | 2020-07-10 | Boehringer Ingelheim International Gmbh | Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas |
EA201101621A1 (ru) | 2009-05-15 | 2012-05-30 | Новартис Аг | Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы |
CN104892502B (zh) | 2009-05-15 | 2017-08-04 | 诺华股份有限公司 | 作为醛固酮合酶抑制剂的芳基吡啶 |
DK2435409T3 (da) | 2009-05-28 | 2014-10-27 | Novartis Ag | Substituerede aminopropionsyrederivater som neprilysininhibitorer |
SG176010A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminobutyric derivatives as neprilysin inhibitors |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
WO2011028455A1 (en) | 2009-09-02 | 2011-03-10 | Merck Sharp & Dohme Corp. | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
JP5934645B2 (ja) | 2009-09-11 | 2016-06-15 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体 |
CN102666533A (zh) | 2009-09-15 | 2012-09-12 | 天蓝制药公司 | 癌症治疗 |
EP2501678B1 (en) | 2009-11-17 | 2015-09-23 | Novartis AG | Aryl-pyridine derivatives as aldosterone synthase inhibitors |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
JP6220126B2 (ja) | 2009-11-23 | 2017-10-25 | セルリアン・ファーマ・インコーポレイテッド | 治療的送達のためのシクロデキストリンに基づく重合体 |
EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
WO2011064376A1 (en) | 2009-11-30 | 2011-06-03 | Novartis Ag | Imidazole derivatives as aldosterone synthase inhibitors |
WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
US8853212B2 (en) | 2010-02-22 | 2014-10-07 | Merck Sharp & Dohme Corp | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes |
JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
CN102791704B (zh) | 2010-03-10 | 2015-11-25 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂 |
BR112012025592A2 (pt) | 2010-04-06 | 2019-09-24 | Arena Pharm Inc | moduladores do receptor de gpr119 e o tratamento de distúrbios relacionados com os mesmos |
EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
BR112012028136A2 (pt) | 2010-05-05 | 2016-08-09 | Boehringer Ingelheim Int | terapia de combinaçao |
EP2571876B1 (en) | 2010-05-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
ES2552657T3 (es) | 2010-05-26 | 2015-12-01 | Satiogen Pharmaceuticals, Inc. | Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
PE20131371A1 (es) | 2010-09-22 | 2013-11-25 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con este |
WO2012049566A1 (en) | 2010-10-14 | 2012-04-19 | Japan Tobacco Inc. | Combination therapy for use in treating diabetes |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9051329B2 (en) | 2011-07-05 | 2015-06-09 | Merck Sharp & Dohme Corp. | Tricyclic heterocycles useful as dipeptidyl peptidase-IV inhibitors |
EP2731947B1 (en) | 2011-07-15 | 2019-01-16 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140243281A1 (en) | 2011-10-28 | 2014-08-28 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
US9115082B2 (en) | 2012-01-18 | 2015-08-25 | Catherine Yang | Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension |
EP2814485A4 (en) | 2012-02-17 | 2015-08-26 | Merck Sharp & Dohme | DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体 |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
EP2874622A4 (en) | 2012-07-23 | 2015-12-30 | Merck Sharp & Dohme | TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS |
TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
JP6295277B2 (ja) | 2013-02-14 | 2018-03-14 | ノバルティス アーゲー | Nep(中性エンドペプチダーゼ)阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体 |
SG11201600211XA (en) | 2013-07-25 | 2016-02-26 | Novartis Ag | Cyclic polypeptides for the treatment of heart failure |
BR112016001376A2 (pt) | 2013-07-25 | 2017-10-24 | Novartis Ag | bioconjugados de polipeptídeos de apelin sintéticos |
WO2015101916A1 (en) | 2013-12-30 | 2015-07-09 | Mylan Laboratories Ltd. | Process for the preparation of empagliflozin |
ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
DE102014018663A1 (de) | 2014-12-13 | 2015-03-05 | Heinz Kiefer | Nachweis von vermehrungsfähigen Zellen zur Überprüfung von Arzneimittel-Wirkstoffangaben bei Zulassungsverfahren |
KR20230151072A (ko) | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태의 치료 방법 |
EA201791668A1 (ru) | 2015-01-23 | 2017-11-30 | Новартис Аг | Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада |
WO2016144862A1 (en) | 2015-03-09 | 2016-09-15 | Intekrin Therapeutics, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
MX2018007681A (es) | 2015-12-28 | 2018-11-14 | Wockhardt Ltd | Composicion farmaceutica osmotica oral de vildagliptin. |
US11013738B2 (en) * | 2016-04-29 | 2021-05-25 | Fundació Hospital Universitari Vall D'hebron—Institut De Recerca | Dipeptidyl peptidase-4 inhibitors for topical eye treatment of retinal neurodegenerative diseases |
US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
EP3606527A1 (en) | 2017-04-03 | 2020-02-12 | Coherus Biosciences, Inc. | Ppar-gamma agonist for treatment of progressive supranuclear palsy |
EP3424927B1 (en) | 2017-07-04 | 2019-04-17 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Efficient process for the preparation of sitagliptin through a very effective preparation of the intermediate 2,4,5-trifluorophenylacetic acid |
EP4360651A2 (en) | 2017-08-24 | 2024-05-01 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
EP3524605B1 (en) | 2018-02-13 | 2019-11-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | New efficient process for the preparation of sitagliptin |
CN113166101A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型(PCSK9)抑制剂的环状五聚体化合物 |
UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
EP3887388A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorders |
WO2021053076A1 (en) | 2019-09-17 | 2021-03-25 | Novartis Ag | Combination therapy with vildagliptin and metformin |
EP4106724A1 (en) | 2020-02-18 | 2022-12-28 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
WO2022029220A1 (en) | 2020-08-05 | 2022-02-10 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE296075C (zh) | ||||
US2961377A (en) | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
DE2009743A1 (de) | 1970-03-03 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Substituierte Biguanide mit antihyperglykämischer Wirkung |
US3960949A (en) | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
CH602612A5 (zh) | 1974-10-11 | 1978-07-31 | Hoffmann La Roche | |
US4935493A (en) | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5433955A (en) | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
DD296075A5 (de) * | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | Verfahren zur herstellung neuer inhibitoren der dipeptidyl peptidase iv |
ATE164852T1 (de) * | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
WO1991017767A1 (en) * | 1990-05-21 | 1991-11-28 | New England Medical Center Hospitals, Inc. | Method of treating inhibition of dipeptidyl aminopeptidase type iv |
JPH04334357A (ja) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
WO1993008259A2 (en) | 1991-10-22 | 1993-04-29 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type iv |
IL106998A0 (en) | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
FR2696740B1 (fr) | 1992-10-13 | 1994-12-30 | Dospharma Sa | Dérivés prodrogués de la diméthylbiguanide et applications comme médicaments. |
WO1995011689A1 (en) | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
JPH07228529A (ja) * | 1994-02-17 | 1995-08-29 | Zeria Pharmaceut Co Ltd | コリンエステラーゼ賦活剤 |
US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
CZ389398A3 (cs) | 1996-05-29 | 1999-07-14 | Prototek, Inc. | Proléčiva thalidomidu a jejich použití pro modulaci funkce T-buněk |
US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
AR016751A1 (es) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
AU3960400A (en) | 1999-03-05 | 2000-09-28 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
-
1996
- 1996-04-25 DE DE122010000020C patent/DE122010000020I1/de active Pending
- 1996-04-25 DE DE19616486.9A patent/DE19616486C5/de not_active Expired - Lifetime
-
1997
- 1997-04-24 SI SI9730802T patent/SI1084705T1/sl unknown
- 1997-04-24 CN CNB2003101131191A patent/CN1269528C/zh not_active Expired - Lifetime
- 1997-04-24 EP EP10184503.0A patent/EP2289513A3/de not_active Withdrawn
- 1997-04-24 KR KR1020077015000A patent/KR100950722B1/ko not_active IP Right Cessation
- 1997-04-24 AU AU30233/97A patent/AU721477C/en not_active Expired
- 1997-04-24 KR KR1020057019835A patent/KR20050104428A/ko active Search and Examination
- 1997-04-24 PT PT119496T patent/PT1084705E/pt unknown
- 1997-04-24 DE DE59703959T patent/DE59703959D1/de not_active Revoked
- 1997-04-24 DK DK00119496.8T patent/DK1084705T3/da active
- 1997-04-24 KR KR1019980707018A patent/KR100617676B1/ko not_active IP Right Cessation
- 1997-04-24 EP EP00119496.8A patent/EP1084705B1/de not_active Expired - Lifetime
- 1997-04-24 CA CA002252576A patent/CA2252576C/en not_active Expired - Lifetime
- 1997-04-24 NZ NZ332707A patent/NZ332707A/xx not_active IP Right Cessation
- 1997-04-24 KR KR1020117031497A patent/KR20120014064A/ko active Application Filing
- 1997-04-24 ES ES00119496.8T patent/ES2505665T3/es not_active Expired - Lifetime
- 1997-04-24 KR KR1020107003160A patent/KR20100036363A/ko not_active Application Discontinuation
- 1997-04-24 AT AT97924866T patent/ATE202705T1/de active
- 1997-04-24 DE DE122007000083C patent/DE122007000083I1/de active Pending
- 1997-04-24 JP JP53845397A patent/JP2001510442A/ja not_active Withdrawn
- 1997-04-24 DK DK97924866T patent/DK0896538T3/da active
- 1997-04-24 PT PT97924866T patent/PT896538E/pt unknown
- 1997-04-24 RU RU98121213/14A patent/RU2189233C2/ru active
- 1997-04-24 EP EP97924866A patent/EP0896538B1/de not_active Revoked
- 1997-04-24 US US09/155,833 patent/US6303661B1/en not_active Expired - Lifetime
- 1997-04-24 ES ES97924866T patent/ES2158562T3/es not_active Expired - Lifetime
- 1997-04-24 CN CN97194017A patent/CN1132578C/zh not_active Expired - Lifetime
- 1997-04-24 DE DE200712000038 patent/DE122007000038I1/de active Pending
- 1997-04-24 WO PCT/DE1997/000820 patent/WO1997040832A1/de not_active Application Discontinuation
-
1999
- 1999-10-06 HK HK99104351A patent/HK1019204A1/xx not_active IP Right Cessation
-
2001
- 2001-05-07 HK HK01103193.8A patent/HK1033420A1/zh not_active IP Right Cessation
- 2001-10-03 GR GR20010401649T patent/GR3036788T3/el not_active IP Right Cessation
-
2007
- 2007-04-18 LU LU91334C patent/LU91334I2/fr unknown
- 2007-04-25 NL NL300280C patent/NL300280I2/nl unknown
- 2007-12-03 NL NL300308C patent/NL300308I2/nl unknown
- 2007-12-05 LU LU91382C patent/LU91382I2/fr unknown
-
2008
- 2008-12-17 JP JP2008320714A patent/JP2009137973A/ja not_active Withdrawn
-
2011
- 2011-12-27 JP JP2011284809A patent/JP2012092136A/ja active Pending
-
2014
- 2014-12-09 LT LTPA2014044C patent/LTPA2014044I1/lt unknown
- 2014-12-09 LT LTPA2014045C patent/LTPA2014045I1/lt unknown
- 2014-12-09 LT LTPA2014043C patent/LTPA2014043I1/lt unknown
- 2014-12-15 LU LU92612C patent/LU92612I2/xx unknown
- 2014-12-15 LU LU92614C patent/LU92614I2/xx unknown
- 2014-12-15 LU LU92613C patent/LU92613I2/xx unknown
- 2014-12-15 LU LU92611C patent/LU92611I2/xx unknown
- 2014-12-15 LU LU92615C patent/LU92615I2/xx unknown
- 2014-12-18 FR FR14C0089C patent/FR14C0089I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1269528C (zh) | 降低哺乳动物血糖水平的二肽基肽酶iv效应物的用途 | |
US20170007582A1 (en) | Use of Dipeptidyl Peptidase IV Effectors for Normalizing the Blood Glucose Level in Mammals | |
EP0995440B1 (de) | Verfahren zur Stiegerung des Blutglukosespiegels in Säugern | |
WO2004080401A2 (en) | Oral insulin therapies and protocol | |
Bertuzzi et al. | Brittle type 1 diabetes mellitus | |
Salvatore et al. | Progress in the oral treatment of type 2 diabetes: update on DPP-IV inhibitors | |
EP1052996B1 (fr) | Medicament pour le traitement des dereglements de l'apoptose contenant des oligosaccharides | |
FREED et al. | Pospisilik et al.(43) Pub. Date: Jan. 17, 2002 | |
KR100336038B1 (ko) | 당뇨병 치료제로서의 티모나식의 신규한 용도 | |
KR20220110506A (ko) | 비만 치료를 위한 글루카곤 및 glp-1 공동-작용제를 사용하는 조합 치료법 | |
Vilsbøll et al. | Incretin hormones and diabetes mellitus | |
Desai et al. | DPP-4 INHIBITORS IN THE TREATMENT OF TYPE-2 DIABETES | |
JP2000327586A (ja) | 糖尿病治療剤 | |
UA71310A (uk) | Спосіб лікування цукрового діабету i типу в експерименті |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: PULOSIDIEA CO., LTD. Free format text: FORMER OWNER: BIOLOGICAL MEDICINE AG Effective date: 20050318 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20050318 Address after: oxford Applicant after: Prosidion Ltd. Address before: Halle, Federal Republic of Germany Applicant before: Biological Medicine AG |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20060816 |